A United States biotech company is closing in on a potential landmark in the global fight against Duchenne Muscular Dystrophy (DMD), one of the most severe and life-limiting genetic diseases affecting children worldwide. REGENXBIO Inc. (NASDAQ: RGNX) has completed enrolment in its pivotal AFFINITY DUCHENNE trial for its gene therapy candidate RGX-202, and is targeting commercial launch by 2027 — a timeline that could fundamentally alter the treatment landscape for a disease that affects roughly one in every 3,500 male births across all populations and geographies.
The milestone arrives at a pivotal moment for the gene therapy sector globally. From the United States to Europe, Japan, and emerging markets, regulators and health systems are grappling with how to evaluate, price, and provide access to one-time genetic interventions that carry transformative promise but also enormous upfront costs. RGX-202's progress places it at the centre of that debate.
A Rivalry That Matters for Patients Globally
Until now, Sarepta Therapeutics' ELEVIDYS has been the sole approved gene therapy for DMD, having received accelerated approval from the US Food and Drug Administration (FDA). Its adoption, however, has been complicated by a significant safety signal: liver injury has been reported in approximately 40% of patients — a rate that has given pause to physicians and payers in the United States and dampened enthusiasm in European markets, where regulators have generally applied stricter benefit-risk assessments to novel biologics.
REGENXBIO is positioning RGX-202 as a safer alternative. In Phase I/II results, all four patients dosed at the pivotal level exceeded expected functional outcomes at the one-year mark, with no serious adverse events, thrombocytopenia, or liver injury reported. The therapy incorporates a CT domain in its microdystrophin construct — a technical distinction the company says no rival has replicated — and is delivered via its proprietary NAV AAV8 vector.
For the international medical community, the safety differentiation is particularly salient. European regulators at the EMA have historically scrutinised liver toxicity in AAV-based gene therapies with considerable rigour, and several programmes have encountered obstacles in EU approval processes as a result. A cleaner hepatic profile could ease RGX-202's path through European regulatory review, which REGENXBIO is already exploring as part of its geographic expansion strategy.
Manufacturing: Solving a Problem That Has Derailed Global Gene Therapy Rollouts
One of the recurring failures in gene therapy commercialisation globally has not been clinical efficacy but manufacturing scale. From Novartis' Zolgensma — approved for spinal muscular atrophy and priced at over $2 million per dose — to bluebird bio's programmes in Europe, supply chain constraints have repeatedly limited access and inflated costs for health systems trying to budget for these therapies.
REGENXBIO has sought to address this risk proactively. Its facility in Rockville, Maryland, houses a 2,000-litre bioreactor — described as the largest in the gene therapy industry — with estimated annual capacity of 2,500 doses of RGX-202. Critically, first commercial batches have already been produced, and the company handles fill and finish in-house, reducing dependence on contract manufacturers and providing greater supply chain resilience. For international health systems considering formulary inclusion, demonstrated manufacturing reliability is often as important as clinical data in procurement decisions.
The Global DMD Burden and Access Inequities
Duchenne Muscular Dystrophy is caused by mutations in the dystrophin gene on the X chromosome and is almost exclusively diagnosed in males. It is progressive and typically fatal, with most patients historically surviving only into their twenties or thirties, though advances in cardiac and respiratory care have extended life expectancy in recent decades in high-income countries.
An estimated 300,000 people worldwide live with DMD, but access to even existing treatments — including the corticosteroids that form the backbone of standard care — varies enormously across income levels and geographies. REGENXBIO's immediate commercial focus is the United States, where it estimates between 10,000 and 15,000 eligible patients, but the company is actively evaluating European expansion. Broader access in lower-income markets, where the disease burden is proportionally no smaller, will depend on pricing decisions and licensing arrangements that have yet to be disclosed.
Financial Position and Strategic Partnerships Signal Confidence
REGENXBIO ended the third quarter of 2025 with $302 million in cash and marketable securities, up from $245 million at year-end 2024, bolstered by a $110 million upfront payment from Japanese pharmaceutical company Nippon Shinyaku and $145 million in net proceeds from other partnership activity. The Nippon Shinyaku deal is itself internationally significant: it provides a pathway for RGX-202 to reach Japan, where DMD has a similar prevalence and where the Pharmaceuticals and Medical Devices Agency (PMDA) has shown growing openness to accelerated review of gene therapies.
The company is also enrolling a confirmatory study of 30 additional patients, including children as young as one year old, to support post-approval commitments — a design choice that broadens the potential label and addresses a key question for paediatric health systems worldwide: how early can intervention begin?
Regulatory Timeline and What Comes Next
Top-line data from the AFFINITY DUCHENNE trial is expected in early Q2 2026. Should results confirm earlier Phase I/II findings, REGENXBIO plans to submit a Biologics License Application to the FDA under the accelerated approval pathway in mid-2026, with a commercial launch targeted for 2027. Parallel regulatory filings in other major markets would be expected to follow, though timelines for Europe, Japan, and other jurisdictions have not yet been disclosed.
For the global rare disease community — patients, families, neurologists, and health economists alike — the next twelve months represent a critical window. If RGX-202 delivers on its early promise, it would not only offer a new option for DMD patients but also strengthen the broader case for gene therapy as a sustainable, scalable approach to rare genetic disease, a case that health systems from London to Tokyo are still in the process of evaluating.